Physiologically active substances

Details Physiologically active substances Physiologically active substances

2007-10-29

2009-11-17

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C549S271000

Reexamination Certificate

active

07619100

ABSTRACT:
The present invention relates to a compound represented by the formula (I):(wherein, R3, R6, R7and R21are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition and is useful as a therapeutic agent for treating solid cancer.

REFERENCES:
patent: 6712617 (2004-03-01), Detmar et al.
patent: 7026352 (2006-04-01), Mizui et al.
patent: 7256178 (2007-08-01), Kotake et al.
patent: 2008/0021226 (2008-01-01), Kanada et al.
patent: 4-352783 (1992-12-01), None
patent: WO-00/75126 (2000-12-01), None
patent: WO-02/12533 (2002-02-01), None
patent: WO-02/060890 (2002-08-01), None
patent: WO-03/099813 (2003-12-01), None
Seki-Asano, Mitsuko et al., “Isolation and Characterization of a New 12-Membered Macrolide FD-895”, J. Antibiot, 1994, vol. 47, No. 12, pp. 1395 to 1401.
Bestmann, Hans Jurgen. Synthesis, 1989, vol. 6, pp. 419-423.
Bestmann, Jans Jurgen. Angew. Chem., 1983, vol. 95, No. 10, pp. 810-811.
Furstner, Alois et al. Efficient Total Syntheses of Resin Glycosides and Analogues by Ring-Closing Olefin Metathesis, J. Am. Chem. Soc., 1999, vol. 121, pp. 7814-7821.
Gunawardana, Geewananda, et al. J. Am. Chem. Soc. 1999, vol. 121, pp. 6092-6093.
Rohr, Jurgen. Angew Chem. Int. Ed., 2000, vol. 39, No. 16, pp. 2847-2849.
Kobayashi, Jun'ichi et al. Tetrahedron Letters, 1996, vol. 37, No. 9, pp. 1449-1450.
Hamberg, Mats. Lipids, 2000, vol. 35, No. 4, pp. 353-363.
Hamberg, Mats. Chem. Phys. Lipids, 1988; vol. 46, No. 4, pp. 235-243.
Sakai et at., “Shinki ko-shuyo kassei busshitsu pladienolide ni kansuru kenkyu (1)-shinki 12-inkan macrolide pladeienolide B no tanri to kozo”, Japan Society for Bioscience, Biotechnology, and Agrochemistry, Taikai Koen Yoshishu, Mar. 2003, p. 123.
Akifumi et al., “Shinki ko-shuyo kassei busshitsu pladienolide ni kansuru kenkyu (2) VEGF sansei yokusei kassei o shihyo to shita pladienolide-rui no kozo kassei sokan”, Japan Society for Bioscience, Biotechnology, and Agrochemistry, Taikai Koen Yoshishu, Mar. 2003, p. 124.
Keiji et al., “Shinki ko-shuyo kassei busshitsu pladienolide ni kansuru kenkyu (3)- pladienolide-rui no yakuri kassei (in vitro, in vivo)”, Japan Society for Bioscience, Biotechnology, and Agrochemistry. Taikai Koen Yoshishu, Mar. 2003, p. 124.
Proceedings for 2003 Annual Meeting of Japan Society for Bioscience, Biotechnology, and Agrochemistry, pp. 123-124, (2003).
Ronald A. Lemahieu et al.; The Journal of Antibiotics, Jul. 1976, vol. 29, No. 7, pp. 728-734.
Roberto Spagnoli et al.; The Journal of Antibiotics, Apr. 1983, vol. 36, No. 4, pp. 365-375.
A. Anadon; Research in Veterinary Science, Jun. 1999, vol. 66, No. 3, pp. 197-203.
D.J. Farrell et al.; Journal of Antimicrobial Chemotherapy, Sep. 2002, vol. 50, Suppl., pp. 39-47.
Eskens et al., “First-in-human clinical, pharmacokinetic (PK) and pharmacodynamic (PD) phase I study of the first-in-class spliceosome inhibitor E7107 administered IV (bolus) on days 1, 8, and 15 every 28 days to patients with solid tumors”, Abstract submission to: American Society of Clinical Oncology, date of submission: Jan. 6, 2009.
Non-Final Office Action dated Mar. 31, 2008 of U.S. Appl. No. 11/473,201.
Notice of Allowability dated Feb. 3, 2009 of U.S. Appl. No. 11/473,201.
Supplemental Notice of Allowability dated Apr. 1, 2009 of U.S. Appl. No. 11/473,201.
Supplemental Notice of Allowability dated Apr. 13, 2009 of U.S. Appl. No. 11/473,201.
Restriction Office Action dated Oct. 4, 2007 of U.S. Appl. No. 10/532,412.
Non-Final Office Action dated Feb. 6, 2008 of U.S. Appl. No. 10/532,412.
Non-Final Office Action dated Aug. 8, 2008 of U.S. Appl. No. 10/532,412.
Final Office Action dated Mar. 4, 2009 of U.S. Appl. No. 10/532,412.
Ryuichi Morishita. “Recent Progress in Gene Therapy for Cardiovascular Disease”, Circ Journal, vol. 66, pp. 1077-1086, Dec. 2002.
Moon-Seok Cha, “Endogenous Production of Nitric Oxide by vascular Endothelial Growth Factor Down-Regulates Proliferation of Choriocarcinoma Cells”, Biochemical and Biophysical Research Communications, vol. 282, pp. 1061-1066, Apr. 2001.

Affiliated with

Also associated with

Rating

Physiologically active substances does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Physiologically active substances, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Physiologically active substances will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4089558